Epitalon Protocol: Anti-Aging and Longevity Guide
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on Epithalamin — the natural bioregulator of the pineal gland, isolated and developed by Professor Khavinson. It is the most extensively studied peptide specifically for longevity endpoints: telomere preservation, cancer incidence reduction, and immune function in ageing populations.
Research context. Epitalon is a research compound. It has been studied in humans, but is not FDA-approved. The longevity data comes primarily from Khavinson's Russian clinical programme. This guide is educational.
How Epitalon Works
Telomerase activation
Epitalon (tetrapeptide Ala-Glu-Asp-Gly) is the most studied telomerase activator in research. It stimulates telomerase expression, reducing the rate of telomere shortening across cell divisions — the primary molecular marker of biological ageing.
Pineal gland support
The pineal gland produces melatonin and regulates the circadian clock, and declines significantly with age. Epitalon is derived from Epithalamin, the natural peptide fraction of the bovine pineal gland. It restores pineal secretory activity, leading to increased melatonin production.
Melatonin regulation
Improved melatonin synthesis is one of the most consistently reported effects of Epitalon, measurable within weeks. This produces downstream effects on sleep quality, circadian rhythm normalisation, antioxidant status (melatonin is a powerful antioxidant), and immune modulation.
Immune modulation
Epitalon influences T-lymphocyte function and NK cell activity. In elderly subjects, it partially restores immune parameters that decline with age — particularly relevant for cancer surveillance.
| Format | Daily Dose | Duration | Frequency | Notes |
|---|---|---|---|---|
| Subcutaneous injection | 5–10 mg/day | 10–20 days | 1–2x per year | Most studied format. Highest bioavailability. Standard Khavinson protocol. |
| Intravenous injection | 5–10 mg/day | 10 days | 1x per year | Used in clinical settings. Faster onset. Not practical for most researchers. |
| Nasal spray | 10–15 mg/day | 10–20 days | 1–2x per year | Lower bioavailability but convenient. Some users report comparable effects at higher dose. |
| Oral (sublingual) | 15–20 mg/day | 10–20 days | 1–2x per year | Lowest bioavailability. Some di/tripeptides survive digestion; Epitalon is a tetrapeptide so survival is partial. |
Khavinson et al. (2003)
Subjects: Elderly subjects (65+) | Duration: 12 years follow-up
Subjects receiving annual Epitalon cycles showed 1.6–1.8x reduction in cancer incidence compared to age-matched controls.
Anisimov et al. (2001–2003)
Subjects: Mice, rats | Duration: Life-span studies
Epitalon extended lifespan by 13–26% in accelerated-ageing rodent models. Reduced tumour incidence. Melatonin pathway confirmed.
Morozov, Khavinson (1996)
Subjects: Healthy subjects | Duration: 10-day cycle
Measurable increase in melatonin secretion within 10-day treatment window. Immune parameters improved in elderly subgroup.
Peptide Detail Profiles
Bioregulator Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →